University of Hertfordshire

From the same journal

By the same authors

Standard

Evaluation of a new topical skin protectant (RD1433) for the prevention and treatment of incontinence-associated dermatitis. / Matar, Hazem; Larner, Joanne; Viegas, Vanessa; Kansagra, Sneha; Atkinson, Karen; Shetage, Satyajit; Skamarauskas, John; Theivendran, Baveetharan; Goldman, Virginia; Chilcott, Robert.

In: Cutaneous and Ocular Toxicology, 23.11.2016.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Matar, Hazem ; Larner, Joanne ; Viegas, Vanessa ; Kansagra, Sneha ; Atkinson, Karen ; Shetage, Satyajit ; Skamarauskas, John ; Theivendran, Baveetharan ; Goldman, Virginia ; Chilcott, Robert. / Evaluation of a new topical skin protectant (RD1433) for the prevention and treatment of incontinence-associated dermatitis. In: Cutaneous and Ocular Toxicology. 2016.

Bibtex

@article{abc1730307ae40fdbde886b8c3bc6992,
title = "Evaluation of a new topical skin protectant (RD1433) for the prevention and treatment of incontinence-associated dermatitis",
abstract = "Context: Incontinence-associated dermatitis (IAD) is a type of moisture-associated dermatitis caused by repeated skin exposure to urine or stool. A product that could mitigate such symptoms would have a significant impact on cost of care and patients{\textquoteright} quality of life. Objective: This study compared the clinical efficacy of RD1433 and a comparator product (Vaseline{\textregistered}) in preventing and treating experimental IAD skin lesions. Materials and methods: For the “prevention” part of the study, skin sites in eight human volunteers were treated daily for five days with either RD1433 or Vaseline{\textregistered} immediately prior to synthetic urine exposure. In the “treatment” part, exposure to synthetic urine was substituted for Vaseline{\textregistered} or RD1433 application on the first two days to promote the development of skin lesions prior to the application of the products from day three. Product efficacy was quantified by visual scoring and an array of biophysical instruments. Results: Both RD1433 and Vaseline{\textregistered} significantly reduced lesion progression when applied as a prophylactic. When applied as a treatment (following establishment of skin lesions), RD1433 demonstrated a statistically significant improvement in several measures of skin function whereas there was no statistically significant improvement following treatment with Vaseline{\textregistered}.Conclusion: The findings of this study suggest that RD1433 may be superior to Vaseline{\textregistered} in the prevention and treatment of experimental IAD lesions. Clearly, further work is required to establish the efficacy of RD1433 with patients in a clinical environment. ",
author = "Hazem Matar and Joanne Larner and Vanessa Viegas and Sneha Kansagra and Karen Atkinson and Satyajit Shetage and John Skamarauskas and Baveetharan Theivendran and Virginia Goldman and Robert Chilcott",
year = "2016",
month = nov,
day = "23",
doi = "10.1080/15569527.2016.1257637",
language = "English",
journal = "Cutaneous and Ocular Toxicology",
issn = "1556-9527",
publisher = "Informa Healthcare",

}

RIS

TY - JOUR

T1 - Evaluation of a new topical skin protectant (RD1433) for the prevention and treatment of incontinence-associated dermatitis

AU - Matar, Hazem

AU - Larner, Joanne

AU - Viegas, Vanessa

AU - Kansagra, Sneha

AU - Atkinson, Karen

AU - Shetage, Satyajit

AU - Skamarauskas, John

AU - Theivendran, Baveetharan

AU - Goldman, Virginia

AU - Chilcott, Robert

PY - 2016/11/23

Y1 - 2016/11/23

N2 - Context: Incontinence-associated dermatitis (IAD) is a type of moisture-associated dermatitis caused by repeated skin exposure to urine or stool. A product that could mitigate such symptoms would have a significant impact on cost of care and patients’ quality of life. Objective: This study compared the clinical efficacy of RD1433 and a comparator product (Vaseline®) in preventing and treating experimental IAD skin lesions. Materials and methods: For the “prevention” part of the study, skin sites in eight human volunteers were treated daily for five days with either RD1433 or Vaseline® immediately prior to synthetic urine exposure. In the “treatment” part, exposure to synthetic urine was substituted for Vaseline® or RD1433 application on the first two days to promote the development of skin lesions prior to the application of the products from day three. Product efficacy was quantified by visual scoring and an array of biophysical instruments. Results: Both RD1433 and Vaseline® significantly reduced lesion progression when applied as a prophylactic. When applied as a treatment (following establishment of skin lesions), RD1433 demonstrated a statistically significant improvement in several measures of skin function whereas there was no statistically significant improvement following treatment with Vaseline®.Conclusion: The findings of this study suggest that RD1433 may be superior to Vaseline® in the prevention and treatment of experimental IAD lesions. Clearly, further work is required to establish the efficacy of RD1433 with patients in a clinical environment.

AB - Context: Incontinence-associated dermatitis (IAD) is a type of moisture-associated dermatitis caused by repeated skin exposure to urine or stool. A product that could mitigate such symptoms would have a significant impact on cost of care and patients’ quality of life. Objective: This study compared the clinical efficacy of RD1433 and a comparator product (Vaseline®) in preventing and treating experimental IAD skin lesions. Materials and methods: For the “prevention” part of the study, skin sites in eight human volunteers were treated daily for five days with either RD1433 or Vaseline® immediately prior to synthetic urine exposure. In the “treatment” part, exposure to synthetic urine was substituted for Vaseline® or RD1433 application on the first two days to promote the development of skin lesions prior to the application of the products from day three. Product efficacy was quantified by visual scoring and an array of biophysical instruments. Results: Both RD1433 and Vaseline® significantly reduced lesion progression when applied as a prophylactic. When applied as a treatment (following establishment of skin lesions), RD1433 demonstrated a statistically significant improvement in several measures of skin function whereas there was no statistically significant improvement following treatment with Vaseline®.Conclusion: The findings of this study suggest that RD1433 may be superior to Vaseline® in the prevention and treatment of experimental IAD lesions. Clearly, further work is required to establish the efficacy of RD1433 with patients in a clinical environment.

U2 - 10.1080/15569527.2016.1257637

DO - 10.1080/15569527.2016.1257637

M3 - Article

JO - Cutaneous and Ocular Toxicology

JF - Cutaneous and Ocular Toxicology

SN - 1556-9527

ER -